# US 2025/0144129 A1 · Pharmaceutical compositions for preventing or treating liver diseases with fibrosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144129 A1
- Document ID: US20250144129A1
- Status: Published application
- Kind: A1
- Application number: 18/939,823
- Filed: 2024-11-07
- Published: 2025-05-08
- Earliest claimed: 2023-11-07
- Assignees: Shibuya Corporation; Yamaguchi University
- Applicants: Shibuya Corporation; Yamaguchi University
- Inventors: Naoki YAMAMOTO; Taro TAKAMI; Toshihiko MATSUMOTO; Daiki KAWAMOTO
- Web page: https://patentgrep.com/patent/US20250144129A1

## CPC

- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 47/6909: {Micelles formed by phospholipids}
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61K 9/5184: {Virus capsids or envelopes enclosing drugs (liposomes with additional exogenous lipids A61K9/127)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

It is an object of the present invention to provide a drug for preventing or treating a liver disease associated with fibrosis, the drug containing microRNAs as an active ingredient. A pharmaceutical composition for preventing or treating a liver disease associated with fibrosis, the pharmaceutical composition containing at least one kind of microRNAs selected from miR 1237-5p, miR 204-3p, miR 7977, miR 6089, and miR 5787 as an active ingredient, is produced.

## Claims

### Claim 1

A pharmaceutical composition for preventing or treating a liver disease associated with fibrosis, the pharmaceutical composition comprising at least one kind of microRNAs selected from miR 1237-5p, miR 204-3p, miR 7977, miR 6089, and miR 5787, or precursors thereof as an active ingredient.

### Claim 2 (depends on 1)

The pharmaceutical composition according to claim 1, further comprising a vehicle for holding the microRNAs or precursors thereof.

### Claim 3 (depends on 2)

The pharmaceutical composition according to claim 2, wherein the vehicle for holding the microRNAs or precursors thereof is any extracellular vesicle selected from an exosome, a microvesicle, a liposome (lipid bilayer), and an apoptotic vesicle.

### Claim 4 (depends on 3)

The pharmaceutical composition according to claim 3, wherein the extracellular vesicle is a mesenchymal stem cell-derived extracellular vesicle.

### Claim 5 (depends on 3)

The pharmaceutical composition according to claim 3, wherein the extracellular vesicle is a cell-derived extracellular vesicle obtained by introducing a polynucleotide encoding at least one kind of microRNAs selected from extraneous miR 1237-5p, miR 204-3p, miR 7977, miR 6089, and miR 5787, or precursors thereof into cells, and allowing the microRNAs or precursors thereof to be expressed therein.

### Claim 6 (depends on 1)

The pharmaceutical composition according to claim 1, wherein the pharmaceutical composition is used in combination with mesenchymal stem cells to be administered to a target.

### Claim 7

An extracellular vesicle derived from cells, obtained by introducing a polynucleotide encoding at least one kind of microRNAs selected from extraneous miR 1237-5p, miR 204-3p, miR 7977, miR 6089, and miR 5787, or precursors thereof into cells, and allowing the microRNAs or precursors thereof to be expressed therein,
the extracellular vesicle comprising at least one kind of microRNAs selected from miR 1237-5p, miR 204-3p, miR 7977, miR 6089, and miR 5787, or precursors thereof.

### Claim 8 (depends on 7)

The extracellular vesicle according to claim 7, wherein the extracellular vesicle is a mesenchymal stem cell-derived extracellular vesicle.

### Claim 9

A culture product obtained by introducing a polynucleotide encoding at least one kind of microRNAs selected from extraneous miR 1237-5p, miR 204-3p, miR 7977, miR 6089, and miR 5787, or precursors thereof into cells, allowing the microRNAs or precursors thereof to be expressed in the cells, and culturing the cells.

### Claim 10

A method for producing extracellular vesicles for suppressing liver fibrosis, the extracellular vesicles containing at least one kind of microRNAs selected from extraneous miR 1237-5p, miR 204-3p, miR 7977, miR 6089, and miR 5787, or precursors thereof, the method comprising the following steps A to C:
step A of introducing a polynucleotide encoding at least one kind of microRNAs selected from extraneous miR 1237-5p, miR 204-3p, miR 7977, miR 6089, and miR 5787, or precursors thereof into mesenchymal stem cells;
step B of culturing the mesenchymal stem cells obtained in step A to obtain a culture product; and
step C of harvesting extracellular vesicles from the culture product.

### Claim 11 (depends on 4)

The pharmaceutical composition according to claim 4, wherein the extracellular vesicle is a cell-derived extracellular vesicle obtained by introducing a polynucleotide encoding at least one kind of microRNAs selected from extraneous miR 1237-5p, miR 204-3p, miR 7977, miR 6089, and miR 5787, or precursors thereof into cells, and allowing the microRNAs or precursors thereof to be expressed therein.

### Claim 12 (depends on 2)

The pharmaceutical composition according to claim 2, wherein the pharmaceutical composition is used in combination with mesenchymal stem cells to be administered to a target.
